SEC Form 4 · accession 0001493152-26-039507
INTERPACE BIOSCIENCES, INC. · IDXG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vijay Aggarwal
Director
Period of report
Aug 20, 2026
Accepted (ET)
Aug 20, 2026 · 5:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001054102
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Aug 20, 2026 | A | 69,252 | A | — | — | Common Stock | 69,252 | 69,252 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.
- F2The restricted stock units vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.